We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Respiratory Medicine

Journal Scan / Research · November 12, 2021

Efficacy and Safety of Suvratoxumab for Prevention of S. aureus Ventilator–Associated Pneumonia

The Lancet Infectious Diseases


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Infectious Diseases
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial
Lancet Infect Dis 2021 Sep 01;21(9)1313-1323, B François, HS Jafri, J Chastre, M Sánchez-García, P Eggimann, PF Dequin, V Huberlant, L Viña Soria, T Boulain, C Bretonnière, J Pugin, J Trenado, AC Hernandez Padilla, O Ali, K Shoemaker, P Ren, FE Coenjaerts, A Ruzin, O Barraud, L Timbermont, C Lammens, V Pierre, Y Wu, J Vignaud, S Colbert, T Bellamy, MT Esser, F Dubovsky, MJ Bonten, H Goossens, PF Laterre

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading